---

---

positive   crawled time : 00:20   

save search

---

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
Published: 2024-02-03 (Crawled : 00:20) - globenewswire.com
FDMT M | $25.29 2.06% 2.02% 630K |

Health Technology

| Email alert Add to watchlist
prism favorable positive trial

---

Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition
Published: 2023-12-10 (Crawled : 00:20) - globenewswire.com
AGIO | $29.52 0.31% 0.3% 750K |

Health Technology

| Email alert Add to watchlist
disease positive cell meeting results study

---

Chair of Sangoma Technologies Corporation Reports Updated Ownership Position
Published: 2023-11-24 (Crawled : 00:20) - globenewswire.com
STHO | $11.89 1.97% 1.93% 36K |

n/a

| Email alert Add to watchlist
SANG | $4.84 2.82% 910 |

Manufacturing

| Email alert Add to watchlist
corporation

---

Astellas Receives Positive CHMP Opinion for VEOZA™ (fezolinetant)
Published: 2023-10-13 (Crawled : 00:20) - biospace.com/
ALPMF | $9.17 43.47% 16K |

Health Technology

| -26.96% | O: -1.86% H: 0.0% C: 0.0%
ALPMY | $9.47 -1.11% 520K |

Manufacturing

| -29.58% | O: -2.78% H: 0.04% C: -0.57%
chmp positive

---

Scilex Holding Company Retains Warshaw Burstein, LLP and Christian Attar Law to Investigate Potential Naked Short Selling, Short Positions, Stock Lending Program Activities and Market Manipulation of Its Stock Price
Published: 2023-10-07 (Crawled : 00:20) - globenewswire.com
SCLX | $0.8812 -2.09% -2.13% 2.1M |

| Email alert Add to watchlist
SRNE | $0.024 -8.85% 57K |

Health Technology

| Email alert Add to watchlist
company program potential market

---

Reviva Pharmaceuticals Announces Positive Safety Data from Drug-Drug Interaction Clinical Study of Brilaroxazine
Published: 2023-08-26 (Crawled : 00:20) - revivapharma.com
RVPH | $3.035 0.5% 0.49% 140K |

| Email alert Add to watchlist
brilaroxazine positive pharmaceuticals study

---

Dfpg Investments LLC Increases Position in MP Materials Corp by … – Best Stocks
Published: 2023-04-22 (Crawled : 00:20) - spacfeed.com
BMAQ | $10.47 3.76% 10K |

| Email alert Add to watchlist
investments

---

Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC
Published: 2023-03-04 (Crawled : 00:20) - globenewswire.com
MLYS M | $11.32 5.3% 5.04% 100K |

| Email alert Add to watchlist
trial therapeutics positive results phase 2

---

Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia
Published: 2023-02-18 (Crawled : 00:20) - prnewswire.com
ATNM | $6.85 2.7% 0.0% 350K |

Health Technology

| Email alert Add to watchlist
leukemia trial positive results

---

Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations at 64th ASH Annual Meeting
Published: 2022-12-10 (Crawled : 00:20) - prnewswire.com
SNDX | $20.82 1.61% 1.59% 850K |

Health Technology

| Email alert Add to watchlist
gment-101 meeting trial positive phase 1

---

Vera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection at the American Society of Nephrology Kidney Week 2022 Annual Meeting
Published: 2022-11-05 (Crawled : 00:20) - globenewswire.com
VERA | $37.96 -3.85% -4.0% 1.4M |

Professional, Scientific, and T...

| Email alert Add to watchlist
mau868 nephropathy meeting kidney virus week trial therapeutics positive results infection phase 2b

---

REGENXBIO Presents Positive Initial Data from Phase II AAVIATE® Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery and Provides Trial Update at Retina Society 54th Annual Scientific Meeting
Published: 2021-10-01 (Crawled : 00:20) - biospace.com/
RGNX | $15.67 -2.73% -2.87% 570K |

Health Technology

| -62.57% | O: 0.5% H: 0.0% C: 0.0%
CLSD P | $1.29 -2.27% -2.33% 230K |

Health Technology

| -78.17% | O: -1.5% H: 0.0% C: 0.0%
treatment positive retina liver trial

---

Xenetic Biosciences Announces Positive Phase 1 Clinical Results for PSA-Oxyntomodulin for the Treatment of Type II Diabetes and Obesity
Published: 2014-05-12 (Crawled : 00:20) - globenewswire.com
BAX | $39.47 -0.45% 0.0% 2.8M |

Health Technology

| Email alert Add to watchlist
XBIO | $4.14 7.32% 770 |

Health Technology

| Email alert Add to watchlist
diabetes treatment obesity phase 1 positive results phase 3 phase 2

---

Gainers vs Losers

67%

33%

Top 10 Gainers

---

Your saved searches

---